This article presents additional next generation data from our preclinical validation study. In total 121 samples (clinical specimen and interlaboratory test samples) were tested successfully with next generation sequencing. 38 different mutations in six different genes were detected. Next to the detection of different mutations, the reproducibility of the NGS test was analyzed. Three samples were analyzed five times and the results were compared. Several mutations classified as non-pathogenic so far, have been detected repeatedly.
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& Common and rare mutations were detected, information on rare mutations could be of interest for further studies on specific mutations.
Many mutations classified as non-pathogenic are detected alongside the analysis of pathogenic mutations, impact of those alterations on therapy is not fully known so far.
Repeatability of the assay is given also for non-pathogenic mutations.
Data
The data represented here is additional data from our pre-clinical validation study (1) . Table 1 shows the mutations, which were detected by NGS in the samples used for a clinical pre-validation in our laboratory. In total 107 pathogenic mutations were detected in the 121 samples tested successfully. 38 different mutations were detected: 4 different mutations in BRAF, 12 in EGFR, 2 in KIT, 9 in KRAS, 5 in NRAS, and 6 in PIK3CA. Common mutations as KRAS c.35G4A (p.G12D), BRAF c.1799T 4A (p.V600E) or EGFR c.2573T 4G (p.L858R) could be detected as well as more uncommon mutations (e.g. KRAS c.351A 4T (p.K117N) or NRAS c.437C4 T (p.A146V)). Table 2 shows mutations, classified as non-pathogenic so far, which were detected in samples used for the testing of the repeatability of the GeneRead QIAact Actionable Insights Tumor Panel. 24 genetic alterations were detected in the Multiplex reference standard; nine respectively eight alterations were detected in the two clinical samples. Except for one mutation, which had a percentage of a mutant (PM) in the background of wild type in the range of the limit of detection, all mutations could be detected with similar frequencies in all five repetitions.
Experimental design, materials and methods
122 samples were tested retrospectively to validate the use of the GeneReader System in our laboratory. One sample proofed to be not suitable for NGS testing and was excluded from the analysis. The GeneRead QIAact Actionable Insights Tumor Panel was used for target enrichment of ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and RAF1. Following target enrichment, library preparation and clonal amplification was done using the GeneRead DNA Library Q Kit and the GeneRead Clonal Amp Q Kit. DNA quality and concentration was determined after target enrichment and library preparation with the QIAxcel DNA High Resolution Kit on the QIAxcel instrument. Sequencing was performed on the GeneReader instrument with the GeneRead Sequencing Q Kit. Qiagen Clinical Insight Software was used for analysis and interpretation of the results. 
